Inovio Pharmaceuticals temettüsü güvende mi?
Inovio Pharmaceuticals, 0 yıldır temettüsünü artırıyor.
Son 10 yıl içerisinde Inovio Pharmaceuticals, yıllık %0 düşürüldü arttırdı.
5 yıllık sürede düştü, dağıtımını %0 oranında artırdı.
Analistler, mevcut mali yıl için %-100,000 oranında bir Temettü indirimi bekliyorlar.
Inovio Pharmaceuticals Aktienanalyse
Inovio Pharmaceuticals ne yapıyor?
Inovio Pharmaceuticals Inc. is a US biotechnology and pharmaceutical company specializing in the development of DNA vaccines and immunotherapies. It was founded in 1979 by Dr. Joseph Kim and is headquartered in Plymouth Meeting, Pennsylvania. Inovio began working on DNA-based vaccines in the late 1990s and developed the Electroporation technology, which facilitates the introduction of DNA molecules into cells. The company has expanded its capabilities over the years and is able to generate immune responses against a variety of viruses and bacteria. They have also made advancements in using their technology to combat cancer. Inovio's business model is based on licensing technologies and collaborating with partners such as pharmaceutical companies, government agencies, and academic institutions. They also offer services for the development and production of DNA-based vaccines for academic and industrial customers. Inovio is divided into different divisions, including DNA vaccines for infectious diseases and oncology, platform technology, and cancer immunotherapy. They offer a wide range of DNA vaccines for infectious diseases such as HPV, HIV, hepatitis B and C, as well as Lassa fever and Ebola. Inovio has also made significant progress in the development of DNA-based immunotherapies for cancer, using Electroporation technology to train and activate T-cells against cancer cells. In terms of products, Inovio has various products in different stages of clinical development, but they have not yet received FDA approval for any of their products. However, they have successfully conducted clinical trials for vaccines such as HPV, which has shown 90% efficacy against the virus. In conclusion, Inovio is a specialized company in the development of DNA-based vaccines and immunotherapy for cancer. Their Electroporation technology has led to significant breakthroughs, and they continue to pursue partnerships and further development. With their focus on research and development and advancing their technologies, it seems that Inovio is on a path of continued success. Inovio Pharmaceuticals, Eulerpool.com'da en popüler şirketlerden biridir.Aktiensparpläne, yatırımcıların uzun vadeli olarak servet inşa etmeleri için çekici bir fırsat sunar. Ana avantajlardan biri, sözde Cost-Average-Effekti'dir: Düzenli olarak sabit bir miktarın hisse senetlerine veya hisse senedi fonlarına yatırılmasıyla, fiyatlar düşükken otomatik olarak daha fazla pay alınır ve fiyatlar yüksekken daha az alınır. Bu, zaman içinde hisse başına daha uygun bir ortalama fiyata yol açabilir. Ayrıca, Aktiensparpläne, küçük miktarlarla bile pahalı hisselere erişim sağlayarak küçük yatırımcılara da kapılarını açar. Düzenli yatırım, ayrıca disiplinli bir yatırım stratejisini teşvik eder ve impulsif alım veya satım gibi duygusal kararları engellemeye yardımcı olur. Bunun ötesinde, yatırımcılar hisselerin potansiyel değer artışından ve yeniden yatırılabilecek temettü dağıtımlarından faydalanır, bu da bileşik faiz etkisini ve böylece yatırılan sermayenin büyümesini artırır.
Inovio Pharmaceuticals hissesi aşağıdaki sağlayıcılarda tasarruf planına uygun: Trade Republic